<DOC>
	<DOCNO>NCT02817516</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple oral dos TAK-828 healthy participant .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Study TAK-828 Escalating Multiple-Doses Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-828 . TAK-828 test evaluate safety , tolerability , pharmacokinetics pharmacodynamics healthy non-Japanese Japanese participant Parts 1 2 , respectively . The study enroll approximately 56 participant . Participants randomly assign ( chance , like flip coin ) receive either TAK-828 matching placebo . This assignment remain undisclosed participant study doctor study ( unless urgent medical need ) . Proposed dos : - Part 1 : TAK-828 15 mg , 45 mg , 75 mg , 100 mg , placebo BID - Part 2 : TAK-828 45 mg , 100 mg , placebo BID All participant ask take solution time day throughout study . This multi-center trial conduct United States .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion : For Parts 1 2 , subject eligibility determine accord follow criterion prior entry study : 1 . In opinion investigator , subject capable understanding comply protocol requirement . 2 . The subject , applicable , subject 's legally acceptable representative , sign date write , informed consent form require privacy authorization prior initiation study procedure include request subject fast laboratory evaluation . 3 . The subject healthy male , healthy female childbearing potential . Females childbearing potential define surgically sterilize ( hysterectomy , bilateral oophorectomy tubal ligation ) postmenopausal ( example , define least 1 year since last regular menses , folliclestimulating hormone [ FSH ] level &gt; 40 international unit per liter [ IU/L ] least 5 year since last regular menses confirm study drug administer ) . 4 . For Part 1 : subject nonJapanese adult , age 18 55 year ( inclusive ) time informed consent first dose study drug . 5 . For Part 1 : subject weighs least 50 kg body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) Screening . 6 . For Part 2 : subject Japanese descent ( bear Japanese parent grandparent ) , age 20 55 year ( inclusive ) time informed consent first dose study drug . 7 . For Part 2 : subject weighs least 45 kilogram ( kg ) BMI 18.5 25 kg/m^2 ( inclusive ) Screening . Exclusion Criteria For Parts 1 2 , subject meet follow criterion qualify entry study : 1 . The subject receive investigational compound within 30 day 5 halflives ( whichever longer ) first dose study drug . 2 . The subject use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) Checkin ( Day 1 ) . Herbal supplement hormone replacement therapy ( HRT ) must discontinue 28 day prior Checkin ( Day 1 ) . As exception , acetaminophen may use dos less equal ( &lt; = ) 1 gram/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . 3 . The subject immediate family member studysite employee dependent relationship studysite employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 4 . The subject history presence disease condition ( find upon review subject 's medical history , physical examination , clinical laboratory test give reasonable suspicion disease ) could interfere study participation safety , contraindicate take TAK828 similar drug class , potentially confound study result ( example , history presence clinically significant neurologic , cardiovascular , pulmonary , hepatic , hematologic , renal , immunologic , metabolic , musculoskeletal , gastrointestinal , endocrine , psychiatric disease ) . It responsibility investigator assess clinical significance ; however , consultation Takeda medical monitor may warrant . 5 . The subject know hypersensitivity component formulation TAK828 . 6 . The subject active infection Screening . 7 . The subject positive urine drug result drug abuse ( define illicit drug use ) Screening Checkin ( Day 1 ) . 8 . The subject history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year , subject drink 7 drinks/week female 14 drinks/week male ( 1 drink=5 ounce [ 150 milliliter { mL } ] wine , 12 ounce [ 360 mL ] beer , 1.5 ounce [ 45 mL ] hard liquor ) within 6 month Screening visit unwilling abstain alcohol drug throughout study . 9 . The subject take take exclude medication , supplement , food product time period list Prohibited Medications , Foods , Products table 10 . If male , subject intend donate sperm course study 14 week last dose study drug . 11 . The subject condition possibly affect drug absorption ( example , gastrectomy ) . 12 . The subject history cancer , except basal cell carcinoma remission least 5 year Screening . 13 . The subject positive test result hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody Screening know history human immunodeficiency virus ( HIV ) infection . 14 . The subject use nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 28 day prior Checkin ( Day 1 ) cotinine test positive Screening Checkin ( Day 1 ) . 15 . The subject poor peripheral venous access . 16 . The subject donate lose 450 mL blood volume ( include plasmapheresis ) transfusion blood product within 30 day prior Day 1 . 17 . The subject Screening Checkin ( Day 1 ) abnormal ( clinically significant ) ECG . Entry subject abnormal ( clinically significant ) ECG must approve , document signature principal investigator medically qualify subinvestigator . 18 . The subject abnormal Screening Day 1 laboratory value suggest clinically significant underlying disease subject follow laboratory abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great ( &gt; ) 3 time upper limit normal ( ULN ) . 19 . The subject creatine kinase isoenzyme MB ( CKMB ) cardiac troponin ULN Screening Day 1 . 20 . If female , subject childbearing potential ( example , premenopausal , sterilize ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>